The present invention relates to a treatment of multiple sclerosis, and includes the extracorporeal treatment of one or more body fluids, such as, for example blood, cerebral-spinal fluid, or lymphatic fluid. A treatment is applied to the extracorporeal body fluid where the treatment targets at ...
Multiple sclerosis (MS) is a common neurological disorder responsible for substantial neurological morbidity. Although it is considered to be an autoimmune demyelinating disease of the central nervous system (CNS), mediated by antigen-specific CD4+ T helper (Th1) T—cells, therapeutic strategies aimed...
Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-β, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in...
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of 2ME2 or a derivative thereof....
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial Compared with other countries, patients with chronic hepatitis C infection in Japan...
Multiple sclerosis is an autoimmune disorder of the central nervous system during which the immune system attacks and destroys the myelin sheath around nerve axons. Most treatments for multiple sclerosis are immunosuppressive and do not alleviate autoimmunity or regenerate the damage already caused. New ...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the diseas...
Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite.HumansMultiple Sclerosis... H Koprowski,SV Spitsin,DC Hooper - 《Annals of Neurology》 被引量: 330发表: 2001年 Uric acid, a natural scavenger of peroxynitrite, in experimental ...
Method For Multiple Sclerosis Treatment and Prophylaxis By Treatment of Leptospira Infection The present invention provides novel therapies and novel prophylactic methods for multiple sclerosis. Also provided are novel diagnostic methods. The invention resides in the finding that multiple sclerosis most likely...
An MRI, which creates an image of the brain or the spinal cord, is used to search for changes within the brain or spinal cord that are unique to multiple sclerosis. What Medications Are Used for the Treatment of Multiple Sclerosis?